The anti-inflammatory mechanisms of Hsp70

Thiago J. Borges1, Lotte Wietor2, Martijn J. C. van Herwijnen2, Femke Broere2, Ruurd van der Zee2, Cristina Bonorino1* and Willem van Eden2

1 Faculdade de Biociências e Instituto de Pesquisas Biomédicas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
2 Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands

*Correspondence: Cristina Bonorino, Departamento de Biologia Celular e Molecular e Instituto de Pesquisas Biomédicas, Pontifícia Universidade Católica do Rio Grande do Sul, Av. Ipiranga, 6690 2° andar, 90680-027 Porto Alegre, Rio Grande do Sul, Brazil. e-mail: cbonorino@pucrs.br

Immune responses to heat shock proteins (Hsp) develop in virtually all inflammatory diseases; however, the significance of such responses is only now becoming clear. In experimental disease models, Hsp administration can prevent or arrest inflammatory damage, and in initial clinical trials in patients with chronic inflammatory diseases, Hsp peptides have been shown to promote the production of anti-inflammatory cytokines, indicating immunoregulatory potential of Hsp. Therefore, the presence of immune responses to Hsp in inflammatory diseases can be seen as an attempt of the immune system to correct the inflammatory condition. Hsp70 can modulate inflammatory responses in models of arthritis, colitis and graft rejection, and the mechanisms underlying this effect are now being elucidated. Incubation with microbial Hsp70 was seen to induce tolerogenic dendritic cells (DCs) and to promote a suppressive phenotype in myeloid-derived suppressor cells and monocytes. These DC could induce regulatory T cells (Tregs), independently of the antigens they presented. Some Hsp70 family members are associated with autophagy, leading to a preferential uploading of Hsp70 peptides in MHC class II molecules of stressed cells. Henceforth, conserved Hsp70 peptides may be presented in these situations and constitute targets of Tregs, contributing to downregulation of inflammation. Finally, an interfering effect in multiple intracellular inflammatory signaling pathways is also known for Hsp70. Altogether it seems attractive to use Hsp70, or its derivative peptides, for modulation of inflammation. This is a physiological immunotherapy approach, without the immediate necessity of defining disease-specific auto-antigens. In this article, we present the evidence on anti-inflammatory effects of Hsp70 and discuss the need for experiments that will be crucial for the further exploration of the immunosuppressive potential of this protein.

Keywords: Hsp70, stress proteins, immunomodulation, adaptive immunity, innate immunity

Hsps ARE IMMUNODOMINANT PROTEINS

Heat shock proteins (Hsp) are highly conserved proteins, from microorganisms through mammals. They are preferentially induced in response to cell stresses including heat shock, oxidative stress, ultraviolet radiation, ischemia-reperfusion injury, viral infections, nutrient deprivation, and chemicals (Lindquist, 1986), protecting cells from injury and promoting refolding of denatured proteins. Hsp are grouped in families according to their molecular weight, and constitutive members of each family can be found in different cell compartments under non-stress conditions, performing chaperone functions (Lindquist and Craig, 1988).

Hsp70 is the most highly conserved protein known to date (Lindquist and Craig, 1988; Elin, 1999; Feder and Hofmann, 1999). It was therefore surprising when Hsp, including Hsp70, were found to be immunodominant antigens. Early studies demonstrated that 10–20% of the T cells recognized Hsp70 of Mycobacterium tuberculosis after experimental mycobacterial immunization (Kauffman et al., 1987). Hsp70 of Mycobacterium leprae was shown to be a prominent antigen in humans infected with M. leprae (Kauffman et al., 1987; Jannsson et al., 1991). Such mycobacterial-Hsp-specific T cell responses have also been observed in healthy individuals, not previously exposed to mycobacterial infections (Munk et al., 1989) and in cord blood (Fischer et al., 1992; Aalberse et al., 2011).

Immunization with Hsp70 of M. tuberculosis (TB-Hsp70) led to a strong IgG response in 7 days without evidence of IgM production (Bonorino et al., 1998), suggesting that antigen-specific T cells able to provide help were already available in naïve mice. Interestingly, a detailed analysis of the peptides recognized by T cells, both in healthy and infected individuals, revealed that some of them were highly conserved (Quayle et al., 1992; Anderton et al., 1995).

Hsp70 AS AN IMMUNOMODULATORY AGENT

It was then hypothesized that, because of their homology with self, bacterial-Hsp would provoke autoimmunity through molecular mimicry with self-proteins. This idea was refuted by the finding that pre-immunization with bacterial-Hsp protected Lewis rats from adjuvant-induced arthritis (van Eden et al., 1988). Subsequently, immunoregulatory features of Hsp were demonstrated in various inflammatory diseases. The literature on immunomodulatory properties of Hsp is vast. In this review, we will focus on Hsp70. Although it may be tempting to generalize observations on different Hsp, it is important to consider that the different families of Hsp show no homology of sequence or structure, and are encoded by different genes, transcribed under the control
of different transcription factors, that are not always activated in coordinate manner. Rather, Hsp are grouped under the same banner because they are commonly induced in similar situations of stress, cooperating to promote cell recovery and protection from injury.

Hsp70 was demonstrated to have a disease suppressive role in experimental models of autoimmunity. One study demonstrated that T cells reactive to peptide 234–252 of TB-Hsp70 suppressed inflammatory responses against Listeria monocytogenes via production of IL-10 (Kimura et al., 1998). The same group later showed that pretreatment with peptide 234–252 of TB-Hsp70 suppressed the development of adjuvant-induced arthritis in Lewis rats, generating T cells that were specific for this peptide, and produced high levels of IL-10, but not IFN-γ (Tanaka et al., 1999). Also the treatment with anti-IL-10 antibody abrogated protection. This peptide showed 58% amino acid identity between rat and mycobacterial Hsp70. Another study revealed that a different peptide of Hsp70, conserved between rat and mycobacteria, protected Lewis rats from development of arthritis when given intranasally (Wendling et al., 2000), preventing disease development by the induction of IL-10 producing T cells. Endogenous Hsp70 presence in the mouse, guaranteed by the presence of heat shock factor 1 (HSF1), its transcription factor, was found to protect from induced colitis (Tanaka et al., 2007). More recently, treatment with whole endotoxin-free TB-Hsp70 inhibited acute rejection of skin and tumor allografts (Borges et al., 2010). Consequently, disease suppressive effects have been observed in the case of both microbial and self (mammalian) Hsp70, some studies using whole protein, some studies using just the peptide, and IL-10 was always important.

How could the conservation of Hsp be reconciled with this apparent predisposition for recognition by the immune system? One idea was that the protective effects of microbial Hsp were related, at least in part, to their capacity to induce T cell responses which were cross-reactive with self-Hsp. Cohen proposed that, to avoid excessive immune responses to both self- and foreign-antigens, the immune system would be selective in its responsiveness and focus on particular immunodominant proteins: the so-called immunological homunculus (Cohen and Young, 1991; Cohen, 2007). Hsp were thus postulated to be such proteins. However, the regulatory capacity of Hsp could not be completely explained by immunodominance and homology between bacterial- and self-Hsp. This was demonstrated in studies using the adjuvant-induced arthritis model, in which Hsp8s, but not other highly immunogenic and conserved proteins of bacterial origin, were found to suppress disease development (Prakken et al., 2001). So, which additional features of Hsp would endow them with the capacity to suppress inflammatory responses? Along the years, different groups have collected evidence on Hsp70 involvement in innate and adaptive immune responses.

**INNATE IMMUNE CELL MODULATION BY Hsp70 – EXTRACELLULAR Hsp70**

The idea that Hsp70 could modulate innate cell function comes from studies that analyzed the interaction of Hsp70, either delivered extracellularly or present in the outer cell membrane/exosomes, with receptors on cells such as monocytes, dendritic cells (DCs) and myeloid-derived suppressor cells (MDSCs). This notion was surprising initially, because Hsp70 was then believed to be an intracellular chaperone. However, studies by Hightower and Guidon Jr. (1989) revealed that Hsp70 could be released from cells, in a mechanism that was independent of blockage of secretory pathways. A series of studies followed, revealing that soluble Hsp70 could be measured in the serum of both healthy and diseased individuals (Pockley et al., 1998), and that this extracellular Hsp70 could be either actively secreted by a non-classical pathway, or released from dying cells, review in De Maio (2011).

Two new functions were then reported for extracellular Hsp70. One study demonstrated that (mammalian) Hsp70–peptide complexes purified from MethA sarcomas could lead to priming of cytotoxic T cell (CTL) responses against these tumors (Udono and Srivastava, 1993). That meant that Hsp70 could probably bind to a membrane receptor in antigen-presenting cells (APCs), and get access to the endogenous route of antigen processing and presentation in MHC class I – i.e., cross-priming. A different group later reported that human Hsp70 could bind to and activate human monocytes, promoting the secretion of inflammatory cytokines, such as TNF-α, IL-1β, and IL-6 (Asea et al., 2000a). Different groups went on to corroborate the findings of the cross-priming abilities of Hsp70 (Delnoye et al., 2002; Kammerer et al., 2002; Unda et al., 2004). However, the findings on the induction of pro-inflammatory cytokines were disputed (Gao and Tian, 2004) when the removal of contaminating endotoxin of the recombinant preparations of human Hsp70 abrogated the induction of TNF-α by this protein. Hsp70 is a molecule with high affinity for hydrophobic moieties (Tian and Gao, 2009) and the efficient removal of LPS and lipid-like contaminants from preparations of Hsp70 proved to be a challenge for those working with this protein. It is thus very likely that the ability of Hsp70 to bind cell surface receptors (see below) and be internalized, activating antigen presentation, which has been verified by independent groups, is independent of the induction of inflammatory cytokines by this protein, which, to this date, is still disputed.

The removal of contaminating endotoxin and lipoepitopes by treatment with Triton X-114, a detergent, revealed that soluble Hsp70 had, in fact, anti-inflammatory properties. It was demonstrated that TB-Hsp70 could modulate cytokine production in blood and synovial cells of arthritis patients. In vitro treatment with endotoxin-free TB-Hsp70 for 48 h induced IL-10 production in peripheral blood mononuclear cells (PBMCs) from rheumatoid arthritis (RA) and reactive arthritis (ReA) patients as well as in normal controls PBMCs (Detanico et al., 2004). Concomitantly, PBMCs from these patients downregulated IFN-γ production (900-fold for RA patients and 750-fold for ReA patients when compared with untreated cells) and up-regulated IL-10 production (900-fold for RA patients and 500-fold for ReA patients). In addition, synovial cells incubated with TB-Hsp70 for 48 h showed a reversal of the inflammatory profile, with an induction of IL-10 (a 4.9-fold increase when compared with cells treated with bovine serum albumin (BSA) and LPS), correlating with a decrease in TNF-α and IFN-γ production. Synovial monocytes from the arthritis patients were the major source of IL-10 induced by TB-Hsp70. In accordance with these findings,
Luo et al. (2008) demonstrated that human Hsp70 downregulated in a concentration-dependent manner the TNF-α-induced production of pro-inflammatory mediators IL-6, IL-8, and MCP-1 in RA fibroblast-like synoviocytes when compared with OVA-treated cells. Thus, Hsp70, both bacterial and human, were shown to be associated with a protective phenotype in arthritis, corroborating the initial findings in adjuvant arthritis.

TB-Hsp70 could also modulate cytokine production in DCs. These cells provide a link between innate and adaptive responses, by presenting antigen to T cells, activating them, and shaping their differentiation into effector phenotypes (Heath and Carbone, 2009; Watowich and Liu, 2010). Production of IL-12 by DCs leads to a Th1 program of differentiation for the antigen-specific CD4+ T cells, while IL-4 production induces a Th2 phenotype. Tolerogenic DCs, however, are characterized by low production of pro-inflammatory cytokines and high production of anti-inflammatory cytokines. It has been shown that cells expressing low levels of both MHC class II and T cell co-stimulatory molecules – such as CD80 and CD86, and that do or do not produce IL-10 and TGF-β, can be tolerogenic (Steinman et al., 2003; Rutella et al., 2006; Morelli and Thomason, 2007).

LPS-free TB-Hsp70 blocked the in vitro differentiation of DCs from bone marrow precursors. When murine bone marrow DCs (BMDCs) were treated with TB-Hsp70 for 24 or 48 h, an inhibition of maturation characterized by a failure to acquire MHC class II and CD86 expression was observed. TB-Hsp70-treated BMDCs had an eightfold increase in IL-10 production when compared with dexamethasone treated cells and produced 1,200-fold less TNF-α than LPS stimulated cells after 48 h of culture (Motta et al., 2007), suggesting not all transcription was inhibited in the treated BMDCs. More recently, a different group demonstrated that soluble inducible human Hsp70 (now known as HSP A1A) can also induce a regulatory phenotype in monocyte-derived DCs (MoDCs; Stocki et al., 2012). They tested three preparations of Hsp70, two commercial ones, with high or medium endotoxin levels, and one more with very low endotoxin levels. Only the Hsp70 preparations with high and medium endotoxin levels induced maturation of MoDCs in culture. The very low endotoxin level Hsp70, however, inhibited the maturation of MoDCs and reduced the capacity of those cells of stimulating allogeneic T cell proliferation. Together, these results indicated that both TB-Hsp70 and human Hsp70 produced a tolerogenic phenotype in DCs, provided that LPS contamination was eliminated.

These findings in DC have an important implication for a regulatory role of soluble forms of Hsp70. Tolerogenic DCs are known to contribute to the creation of a “suppressive environment” facilitating the peripheral generation of peripheral Tregs. Tregs play a crucial role in suppressing the excessive effector immune response that is harmful to the host (Sakaguchi et al., 2008). These cells can be divided into two subphenotypes. The first one is the Foxp3-expressing Tregs that develop in the thymus (nTregs; Feuerer et al., 2009). The second are the cells that are induced in peripheral sites when given appropriate signals by the APCs (iTregs; Shevach, 2006). Tregs produce IL-10 or TGF-β, sometimes both, and actively suppress non-Treg proliferation (Vignali et al., 2008). Low levels of antigen presentation coupled to low co-stimulation have been linked to the differentiation of induced Tregs (nTregs; Jenkins et al., 1990; Steinman et al., 2000; Long et al., 2011). Thus, it was possible that, by modulating the APCs, Hsp70 could lead to the induction of Tregs in the periphery.

Confirming this prediction, soluble TB-Hsp70 was demonstrated to inhibit acute allograft rejection (Borges et al., 2010). When CMS RI/6 tumor cells or skin sections were pre-incubated in a solution with endotoxin-free TB-Hsp70 and then grafted onto a BALB/c host, the tumor cells formed a solid tumor, and skin rejection was delayed for 7–10 days, compared to controls. This effect was abrogated by depletion of Tregs, which were shown to infiltrate the accepted grafts. Interestingly, when soluble TB-Hsp70 was injected subcutaneously, this led to an increase in CD4+CD25+Foxp3+ cells in the draining lymph node, which correlated to a diminished proliferation of lymph node cells in response to a T cell mitogen. The conclusion was that one single pretreatment with TB-Hsp70 could inhibit a powerful in vivo inflammatory process, and this correlated with the presence of Tregs.

The possibility that Hsp70 and Tregs are intimately linked is discussed in detail in the second part of this article (adaptive immunity). In the meantime, we wish discuss one more evidence that Hsp70 can act as an immunosuppressant – and this is related to another discovery, namely that Hsp70 could localize in membranes.

It was shown that Hsp70 (Vega et al., 2008), similarly to Hsc70 (Arispe and De Maio, 2000) could integrate into an artificial lipid bilayer, opening cationic conductance channels, and this ability was associated with the presence of phosphatidilserine (PS; Arispe et al., 2004). Other sphingolipids, such as globotriaosylceramide, have also been reported to enhance Hsp70 insertion into membranes (Gebrmann et al., 2004). This supported previous reports that Hsp70 could be found in the membrane of tumors (Ferrarin et al., 1992; Mulhoff et al., 1995). Hsp70 was not simply associated with a receptor in the membrane, but rather inserted, because it could not be eluted by acid washes, or Triton X-1000 (Vega et al., 2008) and because only one antibody, recognizing a part of the C-terminus, but not antibodies that would recognize the N-terminus, would detect it (Botzler et al., 1998). The presence of Hsp70 in membranes of cells or exosomes of tumors presented one more way of extracellular interactions of Hsp70.

Myeloid-derived suppressor cells are a different, heterogeneous population of cells that are expanded during cancer, inflammation, and infection, with a remarkable ability to suppress T cell responses (Gabrilovich and Nagaraj, 2009). Chalmers et al. (2010) demonstrated, in mice and humans, that membrane-associated Hsp70 found in tumor-derived exosomes (TDEs) restrained tumor immune surveillance by promoting MDSCs suppressive functions. It was demonstrated that TDEs, contained in the tumor cell supernatant of three tumor cell lines, could mediate T cell-dependent immunosuppressive functions of MDSCs. The authors identified that the factor present on the TDEs that induced MDSCs activation was the inducible Hsp70 (HSPA1A) expressed on TDE cell surface. Hsp70 was only present on exosomal fractions, not in other microparticles. These findings indicated that immunosuppressive effects of tumor cells include their potential of inducing functional MDSCs by releasing exosomes expressing Hsp70.
Hsp70 PUTATIVE RECEPTORS AND RESPECTIVE SIGNALING PATHWAYS

Many studies asked the question of how would cells perceive the presence of extracellular Hsp70 (Asea et al., 2002), and Toll-like receptors (TLRs) 2 and 4 (Asea et al., 2002) were first proposed to be receptors for soluble extracellular human Hsp70 – and this was, as discussed above, disputed due to the contamination issue. CD40 (Wang et al., 2001) was then proposed as a receptor for mammalian Hsp70, however a different study (Binder, 2009) refuted this idea, demonstrating that Hsp70 would still bind to cells in CD40 knockout mice. CD91 (Bass et al., 2001) and LOX-1 (Delhaise et al., 2002), two scavenger receptors, were shown to bind Hsp70-antigen complexes, increasing cross-presentation and eliciting a protective immune response against antigen-expressing tumor cells in vivo. Floto et al. (2006) suggested that the presence of extracellular Hsp70 promoted DC aggregation, immune synapse formation between DCs and T cells, and an effector immune response the signaling through the CCR5 chemokine receptor. All these different results generated great confusion. A consistent finding among studies was the ability of extracellular Hsp70 to be internalized and interact with antigen presentation routes, inducing T cell responses to the peptides that associated with this protein. TLRs and CD40 are signaling receptors, rather than endocytic receptors. Scavenger receptors and lectin-like receptors are endocytic receptors, and the signaling events downstream binding and internalization that follows binding are not fully characterized.

A thorough study transfected Chinese hamster ovary (CHO) cells with cDNAs expressing each of these putative receptors, as well as other scavenger receptors and lectins, and studied their interaction with mammalian extracellular Hsp70 (Theriault et al., 2006). The authors reached no binding or interaction of Hsp70 with cells expressing TLR2, TLR4, CD40, or CD91. In a follow-up study, they used the same approach focusing on scavenger receptors (Theriault et al., 2006). They demonstrated that LOX-1, SREC-1, and FEEL-1 bind and internalize Hsp70. However, different forms of Hsp70 (peptide bond or ATP bound) interacted with each of these receptors with different affinities. In summary, what type of Hsp70 receptors was refused by more than one study, different groups provided evidence for scavenger receptors as the likely receptors for extracellular Hsp70.

SIGNALING ROUTES ACTIVATED BY Hsp70

If extracellular Hsp70 indeed interacts with membrane-bound receptors, will it activate signaling pathways associated with these receptors? Few studies approached this issue.

Mitogen-activated protein (MAP) kinase cascade is one of the most ancient and evolutionarily conserved signaling pathways, which is also important for many processes in immune responses (Dong et al., 2002). TLR-associated Hsp70 was found to mediate the suppressive activity of the MDSCs via activation of STAT3 and ERK (Chalmin et al., 2010). An ERK-dependent route for IL-10 production by different immune system cells upon TLR stimulation has been described (Saravia and O’Garra, 2010). It has been suggested that some TLR2 agonists are good inducers of IL-10 production (Dillon et al., 2006; Manicassamy et al., 2009) or in ERK-deficient cells (Agrawal et al., 2006). Besides, differences in IL-10 production by macrophages, myeloid DCs, and plasmacytoid DCs are correlated with different levels of ERK activation in these cells (Saravia and O’Garra, 2010). Borges et al. (in preparation) observed that RMDNs treated with TB-Hsp70 showed a higher expression of phospho-ERK when compared with unstimulated cells, and inhibition of ERK expression with the specific ERK inhibitor PD98059 blocked IL-10 production upon incubation with Hsp70.

STAT3 is associated with IL-10 production and tolerance (Baron, 2006; Dhingra et al., 2011). Also, IL-10R recruits and activates JAK1-STAT3 pathway (Murray, 2006). In contrast, STAT3 can be activated by pro-inflammatory cytokines like IL-6, through IL-6R (Murray, 2007) and Oncostatin M (Halfter et al., 1999). Despite this duality in STAT3 activation, this transcription factor may be activated after IL-10 release induced by TB-Hsp70.

Based on this, we propose a model in which extracellular Hsp70 could regulate innate immune cell function, binding to cell surface receptors (a scavenger or lectin-like receptor), signaling through TLR2 via ERK to induce IL-10 production, resulting in an anti-inflammatory response. This model is depicted in Figure 1.

It is possible to reconcile this model with what has been observed for the cross-priming and pro-inflammatory roles described for this protein? We believe that the next studies should test the possibility that extracellular Hsp70, upon binding to lectin-like or scavenger receptors, uses associated receptors to signal. It is possible that depending on the form of Hsp70 (associated with peptide, with membranes, with nucleotides, peptide-free) it will associate with a different receptor. Another issue that has to be considered is that, while in bacteria, Hsp70 comes from one gene, in mammals, there may be at least eight genes that code for Hsp70 (Kampinga et al., 2009). Bulk preparations of mammalian Hsp70 from cells contain not only the inducible, HSPA1A, but products from other genes as well. And this may also influence the outcome of the experiment. Finally, binding and internalization, followed by antigen presentation, may lead to inflammatory as well as to regulatory responses, depending on which receptor is engaged, as demonstrated in a recent study (Li et al., 2012). The authors verified that targeting an antigen to LOX-1 or DC-ASGPR on the surface of DCs led to internalization and cross-presentation of
**FIGURE 1** | Hsp70 can interact directly with innate immune cells. (A) A possible mechanism of the Hsp70 action is its interaction with dendritic cells (DCs), myeloid-derived suppressor cells (MDSCs), and monocytes. Hsp70 would bind to endocytic receptors, and be endocytosed, gaining access to routes of antigen presentation, modulating the cell phenotype toward a tolerogenic one, leading to the production of the anti-inflammatory cytokine IL-10 and consequently to immunosuppression. In DCs, Hsp70 downregulates CD86 and MHC class II expression, and inhibits TNF-α production. Also, Hsp70 can inhibit IFN-γ by monocytes.

(B) Upon binding to an endocytic, Hsp70 signals through TLR2, resulting in MyD88 activation. The subsequent phosphorylation of ERK can trigger the activation of an undetermined transcription factor that will bind the il-10 gene promoter leading to IL-10 production.

the antigen. However, while targeting to LOX-1 resulted in INF-γamma producing T cells, targeting to DC-ASGPR resulted in IL-10 producing CD4 T cells. Thus, it is possible that, depending on the form of extracellular Hsp70 and the target cell/tissue microenvironment, different outcomes may ensue. If this possibility is verified experimentally, that would in part explain some of the conflicting results previously discussed here. We are now left with the challenge to test these possibilities in order to elucidate the whole potential of Hsp70 as an immunomodulatory agent.

**ADAPTIVE IMMUNITY REGULATION BY Hsp70**

Besides the innate effects discussed above, several adaptive immunity associated mechanisms have been proposed for induction of Hsp-specific Tregs under physiological conditions.

The role of Hsp70 in adaptive immunity to mediate suppression through Tregs could be related to presentation of Hsp70 peptides, or to the modulation of the innate environment as described in the previous section, leading to the induction of Tregs.

The presentation of Hsp70 peptides in MHC molecules could result either from overexpression of endogenous Hsp70 in situations of physiological stress, or from endocytosis of extracellular Hsp. In response to physiological stress, intracellular levels of Hsp70 will rise in the stressed cells which can lead to presentation of Hsp peptides on MHC class I via the default MHC loading route for cytosolic proteins. This pathway includes degradation of the protein by the proteasome, transporter associated with antigen presentation (TAP) mediated translocation to the endoplasmic reticulum and subsequent loading of the peptides on MHC class I molecules (Neefjes et al., 2011). As will be discussed in more detail below, it is now becoming clear that via autophagy, intracellular Hsp can also be loaded on MHC class II molecules. Peptides derived from extracellular Hsp (pathogen-associated or secreted endogenous Hsp) can be presented via endocytic pathways by MHC class II molecules on APCs or on non-APCs upon stimulation with factors like IFN-γ.

The mechanisms leading to production of Hsp-specific Treg can be manifold. Continuous encounter of bacterial-Hsp, in mucosal surfaces such as the gut can be a way to induce bacterial-Hsp-specific Treg, contributing to Hsp-specific mucosal tolerance (van Eden et al., 2005, 2007). Another possibility is the up-regulation of self-Hsp on non-professional APCs in response to various forms of stress in tissues. In the gut lamina propria of many species, MHC class II is also found to be present on non-professional APCs (Stokes et al., 1996). In addition, the inflammatory mediator IFN-γ is known to induce MHC class II in various cell types. Thus, MHC class II presentation of Hsp fragments in the absence

---

*www.frontiersin.org* May 2012 | Volume 3 | Article 95 | 5
of proper co-stimulation may add to the production of tolerogenic or regulatory T cell responses. In addition, presentation of self-Hsp70 conserved peptides in presence of TGF-β (Sela et al., 1999) could lead to Treg induction and/or expansion (Rosenblum et al., 2011). Also, because some self-Hsp70 peptides are not completely identical to their bacterial homolog peptides, such presented self-peptides could function as altered peptide ligands for bacterial-Hsp-specific cells leading to induction of a partially agonistic and therefore downmodulated T cell response (Wauben et al., 1993). Finally, induction of Treg might be reinforced by the increased levels of the immunoregulatory cytokine IL-10, induced upon stress in multiple tissues (Stordeur and Goldman, 1998).

**AUTOPHAGY, LOADING Hsp PEPTIDES ON MHC CLASS II**

To activate CD4 + T cells, peptides should be presented by MHC class II molecules. Cytosolic proteins, like Hsp70, are by default loaded on MHC class I molecules while extracellular proteins will be presented on MHC class II. Thus, another fundamental question can be raised; how do Hsp peptides end up to become presented by MHC class II? The distinct localization between MHC class I and MHC class II loading pathways has been proven incorrect because cytosolic proteins have been eluted from MHC class II and vice versa (Schmid et al., 2007). Autophagy has been initially found as a process to sustain metabolic fitness during food deprivation through bulk protein degradation (Kuma et al., 2004). The role of autophagy in the immune system is only now becoming clear (Schmid and Munz, 2007; Munz, 2009). Two pathways can result in loading of intracellular peptides on MHC class II. First, intracellular proteins can be incorporated in autophagosomes that subsequently fuse with lysosomes for degradation of their cargo (macrophagophagy). In addition, cytosolic proteins can be transported via LAMP2a directly into the lysosome (chaperone mediated autophagy; Munz, 2006; Schmid et al., 2007; Strasburg and Blum, 2007). Recently, the role of autophagy in loading Hsp70 peptides has been described; in human HLA-DR4 + B cells a striking increase of especially Hsp70 peptides was eluted from HLA-DR4 upon induction of autophagy by amino acid deprivation (Deng et al., 2001). Autophagy induction coincided with elevated Hsp70 mRNA levels. In other words, especially under conditions of cell stress, fragments of Hsp70 will be presented on APCs to T cells, possibly initiating a regulatory T cell response.

**PHENOTYPE OF Hsp-SPECIFIC Treg**

The phenotype of Hsp-specific Treg has not been studied in detail. However, since Hsp-specific T cells have been observed in cord blood, some of them will probably be thymus derived (DC4 + CD25 + Foxp3 + ) natural Treg (Sakaguchi et al., 1995; Ting and Bluestone, 2008). Also, Hsp-specific Treg can be induced in the periphery, which potentially leads to induction of several induced Treg subsets. For example, Foxp3 + T1 cells, which are induced by repetitive stimulation with antigen in the presence of IL-10 (Groux et al., 1997; Roncarolo and Battaglia, 2007). Alternately, mucosal exposure of Hsp can produce iTregs, expressing a CD4 + CD25 + Foxp3 + phenotype (Chen et al., 1994; Weiner, 2001). Or, conversion of naive CD4 + CD25 − Foxp3 − cells into induced CD4 + CD25 + Foxp3 + can occur in the presence of IL-2 and TGF-β at low levels of pro-inflammatory cytokines (Horiwitz et al., 2008).

The phenotype of the Hsp-specific Treg may depend on the exposure route. Intraperitoneal (i.p.) immunization with endotoxin-free TB-Hsp70 or OVA as a control resulted in CD4 + CD25 + T cells from Hsp70 immunized mice expressing slightly enhanced levels of regulatory cytokine IL-10, but not increasingly expression of Foxp3 (Wieten et al., 2009a). In contrast, in a study in a mouse atherosclerosis model, oral Hsp administration increased Foxp3 expression (Van Puymbroeck et al., 2007). Enhanced Foxp3 expression, both systemically in the spleen and locally in the inflamed joint, was also found upon up-regulation of endogenous Hsp70 in Peyr’s patches of carvacrol (a co-inducer of Hsp70) fed mice (Wieten et al., 2010). The finding that Foxp3 levels were increased in cells obtained from joint synovial fluid suggested that induced Treg could have actually migrated to the site of inflammation.

In a recent study, after local injection of whole TB-Hsp70, a higher percentage of CD4 + CD25 + Foxp3 + cells in draining lymph nodes compared with local injection with OVA was observed. Moreover, TB-Hsp70 inhibition of lymph node cell proliferation was superior to the inhibition induced by dexamethasone after PHA stimulation. The authors also observed that induction of acute rejection induced by TB-Hsp70 was dependent on CD4 + CD25 + T cells in a skin allograft model (Borges et al., 2010).

To study the phenotype of Hsp-specific Treg in more detail, the expression of the transcription factor Helios in Tregs elicited by Hsp70 treatment, to verify if they are nTregs or iTregs (Thorton et al., 2010), since peripherally induced Tregs do not usually express this molecule. It will also be interesting to see if T cells found at the site of inflammation are Hsp70 specific, and if they indeed express special homing receptors. Future studies should tell us the relative proportions of nTregs and iTregs in Hsp70-specific Tregs, as well as what are the mechanisms by which they can mediate suppression in each of these models.

**SUPPRESSIVE MECHANISM OF Hsp-SPECIFIC Treg**

Hsp-specific Treg will probably use similar suppressive mechanisms as other antigen-specific Treg, like the production of anti-inflammatory cytokines, contact dependent suppression or killing of effector T cells and conversion of APC into a tolerogenic state (Vignali et al., 2008). Most Treg subsets use IL-10 for suppression (Bluestone, 2005). It has been recently demonstrated that Treg IL-10 is important for local responses, and not for the systemic suppression of inflammation (Rubtsov et al., 2008). In previous studies, we showed that cross-reactive Hsp-specific T cell responses coincided with the production of IL-10 (Anderson et al., 1995; Wendling et al., 2006; Prakken et al., 2001). Subcutaneous injection of soluble TB-Hsp70 increased IL-10 production and the number of Tregs in draining lymph nodes when compared with OVA injection (Borges et al., 2010). Moreover, while addressing the role of IL-10 in modulation of Proteoglycan-induced arthritis (PGIA) upon i.p. immunization with TB-Hsp70 and after nasal administration of Hsp70 peptides, it was observed that both treatment strategies enhanced Hsp70-specific T cell proliferation and IL-10 production. TB-Hsp70 immunization failed to rescue IL-10
deficient mice from PGI-A development. In both wild type and IL-10 deficient mice, Hsp70-specific T cell responses were found, but only in wild type mice these responses suppressed arthritis (Wieten et al., 2009a). In addition, increased PG-specific T cell proliferation, IFN-γ and IL-10 production were found in wild type, but not in IL-10 deficient mice. This illustrates that Hsp70 immunization also modified the PG response to a more anti-inflammatory response. It is therefore possible that Hsp70-induced Tregs generated a tolerogenic micro-milieu by their cytokine production that enabled the outgrowth of new Tregs with antigen specificities beyond Hsp and that IL-10 was required for this effect.

These findings emphasize that Hsp-specific Tregs use mechanisms of infectious tolerance for modulation of inflammation. This has been shown before in transplantation (Qin et al., 1993; Borges et al., 2010), type-1 diabetes (Tarbell et al., 2007), and experimental autoimmune encephalomyelitis (EAE; Mekala et al., 2005) models. Besides IL-10, the role of other cytokines associated with Tregs, like IL-35 has not been addressed but might be relevant.

**HOW IMPORTANT IS STRESS-INDUCED Hsp EXPRESSION?**

Hsp expression is up-regulated in virtually every inflammatory condition. Also in autoimmune disease this has been reported; enhanced expression of Hsp60 has been shown in synovial and mononuclear cells of juvenile idiopathic arthritis (JIA) patients (Boog et al., 1992; de Graeff-Meeder et al., 1995). In addition, increased expression of inducible Hsp70 and HSF1 has been shown in the inflamed joint of RA patients (Schett et al., 1998). This has also been seen for RII, an ER restricted Hsp70 family member (Blass et al., 2001) and interestingly enhanced expression in RA synovium was also seen for the constitutive Hsc70 (Schiak et al., 2004).

As mentioned before, stress-induced Hsp expression has been proposed to be important for induction, maintenance, and activation of Hsp-specific Treg. If indeed so, reduced expression of Hsp – like with aging, as also depicted in Figure 2, where a reduced HSF activity leads to a relatively poor capacity to up-regulate Hsp (Rao et al., 1999; Njemini et al., 2003) – can be expected to influence Hsp mediated immune homeostasis and therefore might contribute to development of chronic inflammatory diseases. In fact, Hsp70 polymorphisms have been associated with inflammatory or autoimmune diseases such as Crohn’s disease (Debler et al., 2003), Alzheimer’s disease (Clarimon et al., 2003), pancreatitis (Balog et al., 2005) and with development of graft versus host disease upon allogeneic hematopoietic stem cell transplantation (Boog et al., 1992).

Decreased Hsp expression has been observed in several immune disorders. A low Hsp70 response has also been described in a subtype of Biobreeding (BB) rats with a high susceptibility for development of autoimmune (Bellmann et al., 1997). Similar results have been found in human PRMC from patients with newly diagnosed type-1 diabetes. In that study, stress responses were found to become re-established again in patients with longstanding diabetes, more than 8 months after disease manifestation. So, defective Hsp70 induction coincided with beta cell directed inflammatory activity, and seemed modulated by pro-inflammatory cytokines rather than metabolic factors (Burgart et al., 2008).

To amplify stress-induced Hsp70 expression, a study tested multiple food-derived compounds for their effect on Hsp70 expression (Wieten et al., 2009b). One of the compounds, carvacrol, was identified as a potent enhancer of stress-induced Hsp70 both in vitro and in vivo. Also in vivo, intragastric (i.g.) garage of carvacrol enhanced Hsp70 expression in Peyers patches (Wieten et al., 2010). Carvacrol was used to boost Hsp levels in APCs and this enhanced Hsp-specific T cell hybridoma activation. We also addressed the immunomodulatory potential of carvacrol in vivo and found that i.g. carvacrol treatment specifically boosted Hsp70-specific T cell responses. The finding that adoptive transfer of T cells, isolated from carvacrol treated donor mice, suppressed PGI-A, were indicative of the induction of Treg.

The above mentioned findings suggested that the immune system can recognize and react on altered expression of these proteins.

**PERSPECTIVES**

Hsp expression or Hsp-specific T cell responses have been positively associated with a better disease prognosis in several inflammatory conditions (de Graeff-Meeder et al., 1991; de Kleer et al., 2003). In addition, the immunosuppressive action of Hsp has been demonstrated in multiple rodent disease models. So, it is attractive to speculate that simply enhancing Hsp mediated immunoregulation in either way could be used as therapy. Apparently, this is oversimplified. Depending on multiple factors such as disease etiology and inflammatory status, patient age and genetic background, difficulties will be encountered. In general, defects in for example positive or negative selection in the thymus, IL-2 production by effector T cells or IL-10 or TGF-β production by Tregs can lead to loss of peripheral tolerance as a result of decreased T cell numbers or functioning (Brusko et al., 2008). Some of these defects might also influence Hsp-specific Treg. For example, the findings that Hsp70-induced suppression of arthritis failed in the absence of IL-10 (Wieten et al., 2009a), illustrated that defects in IL-10 production will also influence Hsp-specific Treg. Furthermore, as disease progresses, severe ongoing inflammation has been described to obstruct the effectiveness of antigen-specific Treg (Valencia et al., 2006, Peluso et al., 2007). It is currently not known if Hsp-specific Treg can also be hampered by ongoing inflammation. Recent experiments performed by us (Lotte Wieten, Martijn J. C. van Herwijnen, Femke Broere, Ruurd van der Zee, and Willem van Eden) have indicated that this is not the case, however. Transfer of Hsp70 peptide-induced Tregs were found to suppress ongoing experimental arthritis (van Herwijnen et al., in preparation). Recently, it has been reported that iTreg but not natural Treg can convert into Th17 cells after exposure to IL-6 and TGF-β (Horwitz et al., 2008). Besides Th1 cells, Th17 cells are major pathogenic effector cells in many autoimmune diseases. Whether Hsp-specific Treg can convert into Th17 cells has not been studied, but if so, timing and route of boosting the Hsp response could be important to avoid exacerbation of disease instead of induction of regulation.

Earlier studies have emphasized the pro-inflammatory nature of stress proteins such as the Hsp70 family members. In this
FIGURE 2 | Hsp-specific immunoregulation in the healthy and aged immune system. Self-Hsp-specific T cells reside in the circulation after escape from central tolerance in the thymus. Since Hsp are highly conserved, these self-Hsp-specific T cells can cross-recognize bacterial-Hsp. This T cell population can be expanded after exposure to bacterial-Hsp at mucosal surfaces like the gut or during infection. At mucosal surfaces, these T cells will be directed toward a regulatory phenotype through mechanisms of mucosal tolerance. In addition, T reg induction and maintenance will be promoted by stress-induced Hsp expression in peripheral tissues, because up-regulation of self-Hsp and presentation of Hsp peptides by MHC class II can occur in the absence of co-stimulation. T reg induction will be enhanced by IL-10 produced in response to stress. Furthermore, self-Hsp peptides can function as altered peptide ligands for bacterial-Hsp-specific T cells. During inflammation, Hsp will be induced and presented on professional APCs at the inflammatory site, leading to full activation of Hsp-specific T reg and local dampening ongoing inflammation. In the aged immune system, stress-induced Hsp expression is decreased. Therefore, reduced Hsp inducibility will probably influence both the induction of Hsp-specific T reg in the periphery and their activation during inflammation. Ultimately, this could result in reduced T reg numbers and function.

sense, they were often mentioned as prime examples of so-called DAMPs or damage-associated molecular patterns. It is possible that contaminating microbial components present in partially purified recombinant proteins used in the experiments have contributed to this (Bausinger et al., 2002; Gao and Tian, 2004; Motta et al., 2007). Besides this, there are other arguments to make against a pro-inflammatory role of Hsp (Broere et al., 2011). As discussed here above, experimental evidence in favor of an immunomodulatory role for Hsp70 is accumulating and therefore Hsp70’s immunosuppressive potential seems to constitute a real phenomenon. A more detailed characterization of the molecular pathways activated by Hsp70 in different cell subpopulations is needed. Such studies will allow us to understand and maximize the use of Hsp70 as an anti-inflammatory agent.

ACKNOWLEDGMENTS
Thiago J. Borges and Cristina Bonorino want to thank Dr. Bruno Paim for his support with the figures and CNPq and FINEP for the financial support. This work of Lotte Wieten, Martijn J. C. van Herwijnen, Femke Broere, Ruurd van der Zee, and Willem van Eden was supported by grants of IOP Genomics project nr IGE07004, the European Union FP7 TOLERAGE: HEALTH-F4-2008-20215 and the Dutch Arthritis Association.

Frontiers in Immunology | Inflammation
May 2012 | Volume 3 | Article 95 | 8
Asea, A., Kabingu, E., Stevenson, A., Rehli, M., Kabingu, E., Boch, Arispe, N., Doh, M., Simakova, O., Arispe, N., and De Maio, A. (2000). A TP
www.frontiersin.org May 2012| Volume 3| Article 95 |
Borges et al. Anti-inflammatory role of Hsp70 for the induction of transplant tol-
e46–e50.

Hsc70 and Hsp70 interact with phospho-
and ADP modulate a cation channel
formed by Hsc70 in acidic phospho-
tics of the strong antibody response
to mycobacterial Hsp70: a primary,
cholesterol profile and den-
demic cell maturation.

Lancet 357, 1598–1602.
de Graeff-Maeder, E. R., van den Zeu, R., Rijkers, G. T., Schuurman, H. J., Kais, W., Rehli, J. W., Zegers, B. J., and van Eden, W. (1991). Recognition of human HLA-DRB1 heat shock protein by monomeric cell proteins from patients with juvenile chronic arthritis. Lancet 337, 578–580.

Damp, rather ‘DAMPERs’. Cell Stress Chaperones 3, 425–431.

Borges, T. J., Porto, B. N., Teixeira, M. A., and Calderwood, S. K. (2002). Heat shock proteins, cellular export vesicles, and the Stress Observation Sys-
tem: a form of communication dur-
ing injury, infection, and cell damage. It is never known how far a controversi-
also, Hsp70, and calreticulin. Immunity 14, 305–313.

Bostling, H., Lippeke, D., Ziflah, U., Matte, S., Brandl, P., Casamore, J. P., Muller, S., Haase, J. F., Kramar, C., De la Hale, H., and Hutsua, D. (2002). Endotoxin-free heat shock protein 70 fails to induce APC activa-
tion. Eur. J. Immunol. 32, 3704–3713.

Bellmann, K., Hui, L., Rudolph, J., Burckert, V., and Kohl, H. (1997). Low stress response enhances vulnerability of six cells in diabetes-prone BB rats. Diabetes 46, 225–236.

Bender, R. J. (2003). CD20-independent modulation of mammalian heat shock 70 by antigen-presenting cells. J. Immunol. 169, 6844–6850.

Bae, S., Unnix, A., Ryzhakov, M., Schuman, F., Ungerecht, U., Malheir-
Steinbuhl, S., de Keyser, E., Engler, J. M., and Burmester, G. R. (2005). The stress protein BiP is overexpressed in a major B and T cell tar-
got in rheumatoid arthritis. Arthritis Rheum. 49, 761–772.

Bluestone, J. A. (2005). Regulatory T-
cell therapy: is it ready for the clinic? Nat. Rev. Immunol. 5, 343–349.

Borgmair, Kabik, I., and Langs, A. (2005). HSP70 hom gene polymor-
phism in alognthetic homotransplantation stimulates cytokine production through TLR4, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 6, 479–480.

Asea, A., Rebli, M., Kabingu, E., Boch, J. A., Bu, O., Aaron, P. E., Stevenson, M. A., and Calderwood, S. K. (2002). Novel signal transduction pathway induced by extracellular HSP70 role of toll-like receptor (TLR) 2 and 4.

HSP70 stimulates cytokine production through TLR4 and TLR2, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 6, 479–480.

Asea, A., Kabingu, E., Stevenson, M. A., and Calderwood, S. K. (2002). HSP70 and Hsp27 interact with phospho-histidine on the surface of PC12 cells resulting in a decrease of vul-
ability. FEBS Lett. 518, 1566–1569.

Asea, A., Kabingu, E., Stevenson, M. A., and Calderwood, S. K. (2002). Novel signal transduction pathway induced by extracellular HSP70 role of toll-like receptor (TLR) 2 and 4.

HSP70 stimulates cytokine production through TLR4 and TLR2, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 6, 479–480.

Asea, A., Rebli, M., Kabingu, E., Boch, J. A., Bu, O., Aaron, P. E., Stevenson, M. A., and Calderwood, S. K. (2002). Novel signal transduction pathway induced by extracellular HSP70 role of toll-like receptor (TLR) 2 and 4.

HSP70 stimulates cytokine production through TLR4 and TLR2, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 6, 479–480.

Asea, A., Kabingu, E., Stevenson, M. A., and Calderwood, S. K. (2002). HSP70 and Hsp27 interact with phospho-histidine on the surface of PC12 cells resulting in a decrease of vul-
ability. FEBS Lett. 518, 1566–1569.
Dingling, S., Bagchi, A. K., Laloo, A. L., Sharma, A. K., and Singal, P. K. (2011). Akt regulates IL-10 mediated suppression of TNFα-induced cardiomyocyte apoptosis by suppressing STAT3 phosphorylation. PloS ONE 6, e20659. doi: 10.1371/journal.pone.0020659

Dillon, S., Agrawal, A., van Dyke, T., Landheer, G., Mazzera, L., Koh, A., Makowicki, J., Akira, S., and Paludan, R. (2004). A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J. Immunol. 172, 4733–4743.

Dillon, S., Agrawal, S., Bunney, K., Letetter, J., Denning, T. L., Oswald-Richter, K., Kaurucz, D. J., Kellar, K., Pacz, J., van Dyke, T., Ziegler, S., Unutmaz, D., and Paludan, R. (2008). Yersinia pseudotuberculosis, a stimulator for Th2 and dendritic cells, inducts regulatory antigen-presenting cells and immunological tolerance. J. Clin. Invest. 118, 616–628.

Deng, C., Davis, R. L., and Haralai, R. A. (2012). MAP kinase in the immune response. Annu. Rev. Physiol. 74, 55–72.

Ellis, R. J. (1990). The molecular chaperone concept. Semin. Cell Biol. 1, 1–9.

Fedei, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Frodermann, V., Bagchi, A. K., Laloo, A. L., Sharma, A. K., and Singal, P. K. (2011). Akt regulates IL-10 mediated suppression of TNFα-induced cardiomyocyte apoptosis by suppressing STAT3 phosphorylation. PloS ONE 6, e20659. doi: 10.1371/journal.pone.0020659

Hori, S., Sakaguchi, S., Gamse, J., and Tonegawa, S. (1997). A CD4+ T-cell subset inhibits antigen-specific C T-cell responses and presents endogenous self-antigens. Nature 389, 753–757.

Hori, S., Sakaguchi, S., Gamse, J., and Tonegawa, S. (1997). A CD4+ T-cell subset inhibits antigen-specific C T-cell responses and presents endogenous self-antigens. Nature 389, 753–757.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.

Feder, M. E., and Hofmann, G. E. (1997). The role of antitumor necrosis factor (TNF) in dendritic cells. Crit. Rev. Immunol. 17, 243–282.
Murray, P. J. (2007). The JAK-STAT pathway: unifying molecular motif and peripheral mononuclear blood cells in elderly patients: a role for inflammatory markers. Front Immunol 44, 50–56.

Pellec, L., Fantini, M. C., Fina, D., Caruso, R., Boitrott, M., Macromol. Biol. T. P. Polyk. J., and Monton, C. (2007). IL-2 counteracts the regulatory T-cell-mediated suppression of human CD4+ T lymphocytes. J. Immunol. 178, 732–739.

Peled, A. G., Shepherd, J. J., and Campion, J. M. (1998). Detection of heat shock protein 70 (Hsp70) and anti-Hsp70 antibodies in the serum of normal individuals. J. Immunol. 167, 4147–4153.

Perret, J., Bruce, E., Balensi, G., and Stave, J. E. (2005). Induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 201, 411–416.

Peul, W. V., Santer, P., Hu, Y., Liew, K. F., and Metz, T. (2003). The inducible nitric oxide synthase (iNOS) translocation of the formyl peptide receptor-like 1 (FPR1) is regulated by LPS and TNF-alpha. J. Immunol. 170, 538–542.

Peron, M., Stevens, S. J., and Spiegel, J. H. (2006). Head-to-head comparison of human CD4+ T lymphocyte homing and cytokine expression and HSF1 activation in synovial tissue. J. Immunol. 177, 331–338.

Pennington, J. M., Bantick, S. J., and Birdsall, I. J. (2006). Role of scavenger receptors in the binding and internalization of heat shock protein 70. J. Immunol. 177, 8004–8013.

Peron, M. J., Mambula, S. S., Saraiva, M., Srivastava, P. K., and Calderwood, S. D. (2007). Exogenous HSP70 binding to surface receptors present on antigen presenting cells and endothelial/epithelial cells. FEBS Lett. 579, 1912–1920.

Perondi, L. M., Kotra, P. E., Tran, D. Q., Wohlfert, E. A., Murry, P. E., Beukink, S., and Shevach, E. M. (2010). Expression of Helios, an IkB kinase 1 receptor family member, differentiates thymic-derived from peripheral thymus-derived Foxp3+ regulatory T cells. J. Immunol. 184, 3543–3551.

Perou, C. M., Sørum, P., Gram, L., and Jonassen, K. (2000). Cancer: DNA microarray analysis. Science 290, 83–86.

Perrotti, D., and Schlossman, S. F. (1999). The biology of murine natural killer (NK) cells. Annu. Rev. Immunol. 17, 123–164.

Perret, J. M., and Stave, J. E. (2005). Induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 201, 411–416.

Pilipovic, J. D., and Natvig, J. B. (1992). Urban arthritis are specific features of reactive T cell clones from rheumatoid synovial fluid. J. Immunol. 149, 575–585.

Platzer, A., van Vliet, L., van Eden, W., van der Zee, R., Broekhuizen, R. P., van der Meulen, C. P., van der Meulen, C., and van der Velden, N. C. (2010). Sunlight regulates the expression of the major heat shock protein (hsp) 70 against colitis.

Plas, Y., and Kasten, S. (2007). Regulatory T-cell immune surveillance via self digestion. Annu. Rev. Immunol. 25, 551–585.

Powell, J. W., and Marshall, D. P. (1993). How programming of the immune system to self antigens and allografts in human and mouse. J. Exp. Med. 7, 505–508.
Induction of oral tolerance to HSP60 or an HSP90 peptide activates T cell regulation and reduces arthritic symptoms. Arthritis Res. Ther. 10, 4299–4307.

Vigne, D. A., Collison, L. W., and Workman, C. J. (2008). How regulatory T cells work. Nat. Rev. Immunol. 8, 523–532.

Steinem, C., Multhoff, G., Arispe, T., Gehrmann, M., Diaz, J. C., van Kooten, P. J., Singh, M., Cheng, G., Oehlmann, W., Henney, C. S., and van Eden, W. (2009a). IL-10 reduces the in vivo CpG DNA-mediated Th1 response. J. Immunol. 182, 3269–3277.

Steinem, C., Multhoff, G., Arispe, T., Gehrmann, M., Diaz, J. C., van Kooten, P. J., Singh, M., Oehlmann, W., Henney, C. S., and van Eden, W. (2009b). Hsp70 expression and induction as a readout for detection of immune modulatory components in food. Cell Stress Chaperones 14, 25–37.

Steinem, C., Multhoff, G., Arispe, T., Gehrmann, M., Diaz, J. C., van Kooten, P. J., Singh, M., Oehlmann, W., Henney, C. S., and van Eden, W. (2010). A novel heat-shock protein coinducer boosts stress protein Hsp70 to activate T cell regulation of inflammation in autoimmune arthritis. Arthritis Res. Ther. 12, 1026–1035.

Tanimaru, S., Okada, K., Matsumoto, A., Matsuura, M., Yagitani, H., and Seiya, T. (2011). TLR2-dependent induction of IL-10 and Fcntp1 via CD14+CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS ONE 6, e18833. doi: 10.1371/journal.pone.0018833

Yamazaki, S., Okada, K., Matsuyama, A., Matsuura, M., Yagitani, H., and Seiya, T. (2011). TLR2-dependent induction of IL-10 and Fcntp1 via CD14+CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS ONE 6, e18833. doi: 10.1371/journal.pone.0018833

Seya, T. (2011). TLR2-dependent induction of IL-10 and Fcntp1 via CD14+CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS ONE 6, e18833. doi: 10.1371/journal.pone.0018833

Copyright © 2012 Borges, Wieten, van Herwijnen, Broere, van der Zee, Bonorino, and van Eden. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.